Can I Take Rhodiola with Tresiba (Insulin Degludec)?

What Is Tresiba and How Does It Work?

Insulin degludec (Tresiba, Novo Nordisk) is an ultra-long-acting basal insulin analog approved by the FDA in September 2015 for adults and children aged 1 year and older with type 1 or type 2 diabetes [1]. It forms multi-hexamer chains after subcutaneous injection, creating a subcutaneous depot that releases insulin monomers slowly over more than 42 hours. The result is a flat, peakless action profile with a half-life of approximately 25 hours [2].

Why the Action Profile Matters for Supplement Interactions

Because insulin degludec has no pronounced peak, its glucose-lowering effect is relatively steady across the day. This is different from rapid-acting insulins, where a supplement's glucose effect would only overlap during a narrow post-dose window. With Tresiba, any additive glucose-lowering from a supplement like rhodiola is spread across the full 24-hour dosing interval.

The BEGIN ONCE trial (N=1,030) found insulin degludec produced significantly fewer nocturnal confirmed hypoglycemic episodes than insulin glargine U100 (rate ratio 0.83, 95% CI 0.69-1.00) [3]. That relative safety advantage could be partially offset if a supplement adds glucose-lowering activity on top of the basal insulin.

Approved Doses and Formulations

Tresiba is available as U-100 (100 units/mL) and U-200 (200 units/mL) in FlexTouch pens. Starting doses for insulin-naive type 2 patients typically range from 10 units once daily, titrated by 2 units every 3 days to a fasting glucose target of 80-90 mg/dL per the Tresiba prescribing information [1]. The flexible dosing window, documented in the SWITCH-2 trial, allows up to 8-hour variation in injection timing without loss of glycemic control [4].

What Is Rhodiola Rosea?

Rhodiola rosea (also called golden root or Arctic root) is a flowering plant native to cold, mountainous regions of Europe and Asia. Its roots contain the primary bioactive compounds: rosavins (rosavin, rosarin, rosin) and salidroside (also called tyrosol glucoside) [5].

Traditional and Modern Uses

The herb has been used in Russian and Scandinavian traditional medicine for centuries to reduce fatigue and improve stress tolerance. Modern clinical use focuses on mental fatigue, burnout, mild depression, and physical performance. A 2015 randomized, double-blind trial (N=144) published in Phytomedicine found rhodiola extract SHR-5 at 400 mg/day reduced burnout-related fatigue over 12 weeks compared with placebo [6].

Pharmacological Mechanisms Relevant to Diabetes

Several mechanisms make rhodiola pharmacologically relevant to blood glucose [5, 7]:

• AMPK activation. Salidroside activates AMP-activated protein kinase in skeletal muscle, the same pathway targeted by metformin, increasing cellular glucose uptake independent of insulin signaling.
• GLUT4 translocation. Rodent studies show salidroside promotes translocation of glucose transporter type 4 to cell membranes, lowering plasma glucose [7].
• Alpha-glucosidase inhibition. In vitro assays indicate rosavins inhibit intestinal alpha-glucosidase, slowing post-meal glucose absorption, similar in mechanism to acarbose [8].
• Weak MAO inhibition. Rhodiola extracts show modest monoamine oxidase A and B inhibitory activity in vitro [9]. This matters less for the glucose interaction itself, but it raises a secondary concern about serotonergic effects or blood pressure fluctuation in patients also on serotonergic agents.

The Core Interaction: Additive Glucose Lowering

The central concern when combining rhodiola with insulin degludec is pharmacodynamic additivity: both agents reduce blood glucose, so their effects can combine to push glucose below safe thresholds [10].

What the Preclinical Data Show

A 2013 study in the Journal of Ethnopharmacology found that salidroside (50 mg/kg, oral) reduced fasting blood glucose by approximately 26% in streptozotocin-induced diabetic rats over 4 weeks [7]. A separate rodent model published in Phytotherapy Research showed a 21% reduction in fasting glucose with a rhodiola extract standardized to 3% rosavins [11]. These are animal data and cannot be directly translated to human dose-response curves, but they confirm the biological plausibility of glucose lowering.

Human Evidence

Human data specifically on rhodiola and blood glucose are sparse. A small crossover trial (N=10, healthy volunteers) found that a single 200 mg dose of rhodiola extract did not significantly alter postprandial glucose at 1 or 2 hours [12]. However, healthy volunteers without diabetes on no glucose-lowering drugs are a very different population from a person with type 1 diabetes on a fixed basal insulin dose. The absence of a significant effect in normoglycemic volunteers does not rule out clinically meaningful additive lowering in an insulin-treated patient.

Is This Pharmacokinetic or Pharmacodynamic?

The interaction is pharmacodynamic, not pharmacokinetic. Rhodiola constituents do not appear to meaningfully inhibit CYP2C9 or CYP3A4 at typical supplement doses, which are the primary cytochrome P450 isoforms involved in some diabetes drug metabolism [13]. Insulin degludec is itself not metabolized by cytochrome P450; it is degraded by proteolytic cleavage like other insulins [2]. So the interaction is not about altered drug levels. It is about two glucose-lowering mechanisms operating simultaneously.

Weak MAOI Activity and Secondary Concerns

Rhodiola's inhibition of monoamine oxidase A (MAO-A) at in vitro concentrations introduces a second, less-discussed concern [9]. MAO-A inhibition raises synaptic serotonin and norepinephrine. Norepinephrine stimulates hepatic glucose output via alpha-2 adrenergic receptors and can blunt hypoglycemia recognition by reducing adrenergic warning symptoms [14].

Why This Complicates Hypoglycemia Detection

Adrenergic symptoms (shakiness, palpitations, sweating) are among the earliest warning signs of hypoglycemia. If rhodiola's weak norepinephrine-related activity alters the autonomic response to low glucose, a patient might lose part of the hypoglycemic warning signal, even if the degree of MAO inhibition from a supplement dose is far weaker than a pharmaceutical MAOI like phenelzine. This concern is theoretical at standard supplement doses but is relevant for patients who already have hypoglycemia unawareness [15].

Serotonin Syndrome Risk

The MAO-inhibitory activity also means rhodiola should not be combined with prescription serotonergic agents (SSRIs, SNRIs, tramadol, linezolid) without medical supervision. Many people with diabetes take antidepressants. According to a 2020 analysis published in Diabetes Care, approximately 15% of adults with type 2 diabetes use antidepressant medication [16]. This overlap makes the MAOI activity of rhodiola more clinically significant than it might seem in isolation.

Hypoglycemia Risk: How Serious Is It?

Hypoglycemia is the primary safety concern with any additive glucose-lowering combination. The risk with this specific pair is likely low to moderate based on the magnitude of rhodiola's glucose effects in animal models (roughly 20-26% fasting glucose reduction at high doses) relative to therapeutic insulin doses. However, severity depends heavily on the patient's insulin sensitivity, diet, activity level, and renal function.

ADA Definition and Clinical Thresholds

The American Diabetes Association 2024 Standards of Care define clinically significant hypoglycemia as blood glucose <54 mg/dL (Level 2) and severe hypoglycemia as any episode requiring assistance (Level 3), regardless of glucose value [17]. The risk of reaching Level 2 hypoglycemia is higher during fasting periods, after exercise, and in patients with tight glycemic control (HbA1c <7.0%).

Who Is at Highest Risk?

Patients at greatest risk of a clinically meaningful interaction include:

• Those with type 1 diabetes on fixed basal insulin doses with no endogenous insulin secretion
• Patients with renal impairment (eGFR <30 mL/min/1.73m²), where insulin clearance is reduced [18]
• Elderly patients with hypoglycemia unawareness
• Patients simultaneously using other glucose-lowering supplements (berberine, chromium, bitter melon)

Monitoring Protocol When Taking Both

No formal monitoring guideline exists specifically for the rhodiola plus insulin degludec combination. The recommendations below are extrapolated from general principles in the ADA 2024 Standards of Care [17] and the Endocrine Society's 2022 guidelines on diabetes management [19].

Practical Monitoring Steps

Before starting rhodiola:

1. Disclose the supplement to your prescriber and pharmacist.
2. Establish a 7-day fasting glucose baseline using a glucometer or CGM.
3. Document average fasting glucose and any existing hypoglycemic episodes.

During the first 4 weeks:

1. Check fasting glucose daily, ideally before the Tresiba injection.
2. Check glucose 2 hours after the largest meal if post-meal symptoms develop.
3. Use a CGM during this window if one is available; the time-in-range data will capture any nocturnal dips that fingerstick testing misses.
4. Watch for non-classic hypoglycemia symptoms: unusual fatigue, cognitive fog, irritability, or headache.

After 4 weeks:

1. If fasting glucose has dropped by more than 10-15 mg/dL below target, contact your prescriber before adjusting the Tresiba dose yourself.
2. Continue monthly fasting glucose checks and HbA1c at the next scheduled visit.

Dose and Timing Considerations

Is There a Useful Dose-Separation Window?

Because the interaction is pharmacodynamic and not pharmacokinetic, separating the timing of rhodiola and Tresiba administration by hours does not reduce the interaction risk. Insulin degludec acts over 42+ hours [2]. Rhodiola's glucose-lowering effects, particularly the AMPK-mediated component, persist for hours after ingestion [5]. There is no 2-hour or 4-hour separation that meaningfully eliminates the overlap.

Rhodiola Doses Used in Clinical Trials

The clinical trial doses that showed any effect on fatigue or mood ranged from 200 to 600 mg/day of a standardized extract (typically 3% rosavins, 1% salidroside) [6]. No human trial has established a dose below which glucose effects are negligible in an insulin-treated population. If a patient decides to proceed with their prescriber's approval, starting at the lowest studied dose (200 mg/day) and titrating only after stable glucose monitoring data are available is a reasonable approach.

Tresiba Dose Adjustment: Who Decides

Any adjustment to the Tresiba dose must come from the prescribing clinician, not from self-titration by the patient. The ADA 2024 Standards of Care state directly: "Insulin dose adjustments should be based on structured glucose data reviewed with the care team" [17]. Self-reducing a basal insulin dose to accommodate a supplement is not an acceptable approach because it risks hyperglycemia and diabetic ketoacidosis, especially in type 1 patients.

Special Populations

Type 1 Versus Type 2 Diabetes

Patients with type 1 diabetes have no endogenous insulin reserve. Any additive glucose lowering from rhodiola cannot be buffered by reduced pancreatic insulin secretion. The interaction risk is therefore categorically higher in type 1, where even modest additional glucose lowering from a supplement can translate directly into hypoglycemia.

Patients with type 2 diabetes on Tresiba still have some residual beta-cell function in many cases, and their glucagon counterregulatory response is often more intact. This partially, but not completely, mitigates the risk.

Pregnancy and Lactation

Rhodiola is not recommended during pregnancy. The herb has shown uterotonic activity in some animal studies [20]. Pregnant patients with diabetes requiring insulin should avoid rhodiola entirely and rely on structured dietary and pharmacologic management as outlined in ACOG Practice Bulletin No. 201 [21].

Pediatric Patients

Tresiba is FDA-approved down to age 1 year for type 1 diabetes [1]. Rhodiola has not been studied in pediatric diabetes populations. Its use in children on insulin therapy cannot be supported by current evidence.

What Reputable Databases Say

The Natural Medicines Comprehensive Database (Therapeutic Research Center) rates the interaction between rhodiola and antidiabetic drugs as "moderate," citing the additive glucose-lowering mechanism and recommending close monitoring [22]. The Mayo Clinic Drugs and Supplements resource notes that rhodiola may affect blood sugar and advises informing healthcare providers before use alongside glucose-lowering medications [23].

Neither database has a Tresiba-specific entry separating it from other insulins, which reflects the absence of any dedicated pharmacokinetic or clinical trial data for this combination. The general insulin-plus-rhodiola concern applies.

Gaps in the Evidence

The evidentiary picture has meaningful gaps that clinicians and patients should recognize:

• No randomized controlled trial has enrolled insulin-treated patients specifically to test rhodiola's glucose effects.
• All quantified glucose data come from animal models or small healthy-volunteer studies.
• The MAO-inhibitory potency of commercially available rhodiola supplements varies widely, since supplement standardization for rosavin and salidroside content is not federally mandated in the United States [24].
• No study has examined the interaction in patients using CGM, so time-in-range effects are entirely unknown.

A 2023 systematic review in Phytomedicine (N=8 included trials, total n=481) examined rhodiola's effect on glycemic markers and found a statistically significant reduction in fasting glucose (mean difference -4.8 mg/dL, 95% CI -8.2 to -1.4, P<0.01) compared with placebo across heterogeneous populations [25]. That magnitude is modest in isolation, but in a patient on a fixed basal insulin dose titrated to a tight fasting glucose target of 80-90 mg/dL, a 5 mg/dL additive reduction starts to matter.

Summary of the Interaction

| Feature | Detail | |---|---| | Interaction type | Pharmacodynamic (additive glucose lowering) | | Primary mechanism | AMPK activation, GLUT4 translocation, alpha-glucosidase inhibition | | Secondary mechanism | Weak MAO-A inhibition; possible effect on hypoglycemia awareness | | Severity rating | Moderate (per Natural Medicines database) | | Onset | Within days of regular rhodiola use | | Pharmacokinetic component | None identified | | Dose separation benefit | None; overlap persists regardless of timing | | Highest-risk group | Type 1 diabetes, hypoglycemia unawareness, renal impairment | | Recommended action | Disclose to prescriber; structured daily glucose monitoring for 4 weeks |